



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: April 24, 2009

To: Primary Clinical Research Associates

From: Alicia Elsing
Research Protocol Specialist III

Re: N0821, A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (Age \geq 70 yrs) with Good Performance Status (PS $<$ 2)

A discrepancy between Section 3.12 of the protocol and the Eligibility Checklist has been found. Therefore, the Eligibility Checklist has been corrected as follows:

Histologic or cytologic confirmation of Stage IV nonsquamous NSCLC or Stage IIIB nonsquamous NSCLC (symptomatic pleural effusions should be drained prior to registration).

- Mixed histology allowed if all components consistent with NSCLC. Patients whose tumors have **predominantly** squamous cell ~~histology/features~~ **component** are NOT eligible.

Please begin using this updated version immediately.

If you have any questions, please feel free to contact me at elsing.alicia@mayo.edu or 507-538-3893.

Enclosure